CD274 and neoplasm: Moreover, this oncolytic virus, which activates the neoantigen-specific T cell response by the synergistic action of PD-L1 inhibition, GM-CSF, and viral oncolysis in the tumor microenvironment may be advantageous to the therapies with PD-1/PD-L1 antibodies.